All News

If approved, avatrombopag (Doptelet) would also be indicated for the treatment of chronic immune thrombocytopenia in patients who have had insufficient response to a previous therapy.

Although malignant melanoma incidence has stabilized or declined in women, melanoma-associated mortality rates have risen among men throughout the world.

Top news of the day from across the health care landscape

Top news of the day from across the health care landscape

Top news of the week from Specialty Pharmacy Times.

The action will increase access to diagnostic tools for healthcare providers who may not have otherwise been equipped to perform tests.

New data presented at the 2018 ACR/ARHP Annual Meeting shows that the treatment regimens for many patients are not being changed to reach a “treat-to-target” goal for low disease activity.

An up-to-date analysis of melanoma mortality rates show that deaths among men are rising, but stabilizing or decreasing in women.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Selinexor is indicated for patients with previously treated diffuse large B-cell lymphoma who are ineligible to receive high-dose chemotherapy with stem cell rescue or CAR T-cell therapy.

Interferon lambda 4 represents a vulnerability that benefits hepatitis C virus to the detriment of humans.

The product has an estimated market size of $338M for the 12 months ending August 2018 according to IQVIA.

Seattle Genetics submitted an application for the expanded use of brentuximab vedotin (Adcetris) in combination with a chemotherapy regimen for patients with peripheral T-cell lymphoma.

Prescriptions for hormonal therapy medications increased in states that expanded Medicaid, according to a recent analysis.

Officials with the FDA have granted Priority Review to dupilumab (Dupixent, Sanofi) for moderate-to-severe atopic dermatitis in adolescent patients aged 12 to 17 years.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.

Chronic liver disease and cirrhosis can contribute to the development of liver cancer, which affects approximately 33,000 individuals in the United States each year.

Treatment regimens consisting of daclatasvir plus sofosbuvir plus ribavirin and velpatasvir/sofosbuvir plus ribavirin show similar cure rates in patients with hepatitis C virus genotype 2 and 3.

Elotuzumab (Empliciti) with pomalidomide and dexamethasone (Pd) is the first triplet combination to be approved based on a randomized clinical trial using Pd as a comparator.

Officials with the FDA have approved elotuzumab (Empliciti) injection for intravenous use in combination with pomalidomide and dexamethasone for the treatment of certain patients with relapsed or refractory multiple myeloma.

Medication nonadherence is a major cause of morbidity, especially in elderly patients.

The product has an estimated market size of $338M for the 12 months ending August 2018 according to officials with IQVIA.

If approved for this indication, dupilumab (Dupixent) will be the first systemic biologic medicine to treat adolescents with moderate-to-severe atopic dermatitis.

The FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent® (dupilumab) in adolescent patients aged 12 to 17 years with moderate-to-severe atopic dermatitis.

Targeting interleukin (IL)-17A and IL-22 proteins may help delay the development of hepatic fibrosis.

Officials with the FDA have approved a new opioid, (Dsuvia, AcelRx Pharmaceuticals), sparking some controversy in the media that the opioid has potential for abuse.

Top news of the day from across the health care landscape.

Top news of the day from across the health care landscape.